HomepageBT3 • FRA
add
BioTime
Vorige slotkoers
€ 0,57
Dag-range
€ 0,52 - € 0,52
Jaar-range
€ 0,46 - € 1,33
Beurswaarde
121,23Â mln. USD
Gem. volume
514,00
Koers/winst
-
Dividendrendement
-
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 3,78Â mln. | 203,29% |
Bedrijfskosten | 4,41Â mln. | 9,13% |
Netto inkomsten | -3,03Â mln. | 57,33% |
Netto winstmarge | -80,29 | 85,93% |
Winst per aandeel | -0,02 | 50,37% |
EBITDA | -3,70Â mln. | 43,35% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 32,71Â mln. | -20,86% |
Totale activa | 96,59Â mln. | -9,00% |
Totale passiva | 31,80Â mln. | -19,48% |
Totaal aandelenvermogen | 64,79 mln. | — |
Uitstaande aandelen | 188,84 mln. | — |
Koers-boekwaardeverhouding | 1,63 | — |
Rendement op activa | -9,63% | — |
Rendement op kapitaal | -13,98% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -3,03Â mln. | 57,33% |
Operationele kasstroom | -5,79Â mln. | -14,89% |
Kasstroom uit beleggingen | 3,89Â mln. | 83,22% |
Kasstroom uit financiering | -3,00K | -100,37% |
Nettomutatie in liquide middelen | -1,86Â mln. | 23,86% |
Vrije kasstroom | -2,27Â mln. | 12,27% |
Over
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Opgericht
1990
Website
Werknemers
72